Table 2 Multivariable analysis for independent impact of risk factors on event-free and overall survival (backward selection of univariate significant variables)
Population | Variable | P-value | HR | 95% CI |
|---|---|---|---|---|
Event-free survival | ||||
ITT | Stage (stages1/2/3/4S and MNA vs. stage 4 and age >1 year) | 0.008 | 0.407 | (0.209–0.793) |
MYCN amplification (no vs. yes) | 0.030 | 0.604 | (0.383–0.952) | |
Response to induction chemotherapy (CR/VGpR vs. pR/MR/SD) | 0.010 | 0.594 | (0.400–0.882) | |
LDH at diagnosis (raised vs. normal) | 0.065 | 2.088 | (0.957–4.559) | |
Result of randomisation (MT vs. ASCT) | 0.007 | 1.705 | (1.159–2.508) | |
AT | Stage (stages1/2/3/4S and MNA vs. stage 4 and age >1 year) | 0.074 | 0.537 | (0.271–1.062) |
MYCN amplification (no vs. yes) | 0.038 | 0.610 | (0.382–0.973) | |
Response to induction chemotherapy (CR/VGpR vs. pR/MR/SD) | 0.027 | 0.622 | (0.408–0.948) | |
Treatment arm (MT vs. ASCT) | 0.011 | 1.667 | (1.125–2.471) | |
TAR | Treatment arm (MT vs. ASCT) | 0.010 | 1.856 | (1.162–2.963) |
Overall survival | ||||
ITT | Stage (stages1/2/3/4S and MNA vs. stage 4 and age >1 year) | 0.002 | 0.325 | (0.160–0.661) |
MYCN amplification (no vs. yes) | 0.001 | 0.439 | (0.273–0.706) | |
Response to induction chemotherapy (CR/VGpR vs. pR/MR/SD) | 0.003 | 0.533 | (0.351–0.810) | |
LDH at diagnosis (raised vs. normal) | 0.063 | 2.225 | (0.958–5.170) | |
Result of randomisation (MT vs. ASCT) | 0.009 | 1.724 | (1.144–2.597) | |
AT | Stage (stages1/2/3/4S and MNA vs. stage 4 and age >1 year) | 0.019 | 0.418 | (0.201–0.866) |
MYCN amplification (no vs. yes) | 0.005 | 0.489 | (0.298–0.803) | |
Response to induction chemotherapy (CR/VGpR vs. pR/MR/SD) | 0.006 | 0.534 | (0.341–0.835) | |
LDH at diagnosis (raised vs. normal) | 0.101 | 2.037 | (0.869–4.774) | |
Treatment arm (MT vs. ASCT) | 0.079 | 1.454 | (0.957–2.208) | |
TAR | Stage (stages1/2/3/4S and MNA vs. stage 4 and age >1 year) | 0.066 | 0.442 | (0.185–1.057) |
MYCN amplification (no vs. yes) | 0.003 | 0.426 | (0.241–0.753) | |
Response to induction chemotherapy (CR/VGpR vs. pR/MR/SD) | 0.067 | 0.600 | (0.347–1.037) | |
Treatment arm (MT vs. ASCT) | 0.014 | 1.903 | 1.142–3.172) | |
